KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Capital Expenditures: 2018-2025

Historic Capital Expenditures for Adaptive Biotechnologies (ADPT) over the last 7 years, with Sep 2025 value amounting to $409,000.

  • Adaptive Biotechnologies' Capital Expenditures rose 18.90% to $409,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 50.78%. This contributed to the annual value of $3.7 million for FY2024, which is 65.75% down from last year.
  • Adaptive Biotechnologies' Capital Expenditures amounted to $409,000 in Q3 2025, which was down 37.56% from $655,000 recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Capital Expenditures peaked at $22.0 million during Q2 2021, and registered a low of $80,000 during Q4 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $1.3 million (2023), whereas its average is $1.5 million.
  • Per our database at Business Quant, Adaptive Biotechnologies' Capital Expenditures soared by 873.97% in 2021 and then slumped by 93.84% in 2024.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Capital Expenditures stood at $9.2 million in 2021, then tumbled by 72.50% to $2.5 million in 2022, then crashed by 48.94% to $1.3 million in 2023, then plummeted by 93.84% to $80,000 in 2024, then climbed by 18.90% to $409,000 in 2025.
  • Its Capital Expenditures stands at $409,000 for Q3 2025, versus $655,000 for Q2 2025 and $1.3 million for Q1 2025.